Advertisement

Topics

Regeneron beats profit estimates, lifts Eylea's growth view

04:56 EDT 3 Aug 2017 | Reuters

(Reuters) - Regeneron Pharmaceuticals Inc's quarterly profit handsomely beat estimates on strong demand for its flagship Eylea drug, helping the U.S. drugmaker raise its full-year growth forecast for the eye treatment.

Original Article: Regeneron beats profit estimates, lifts Eylea's growth view

NEXT ARTICLE

More From BioPortfolio on "Regeneron beats profit estimates, lifts Eylea's growth view"

Quick Search
Advertisement
 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...